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Summary We evaluated the clinical performance of assays measuring intact human chorionic gonadotropin
alone (i-hCG), intact and nicked human chorionic gonadotropin (i-hCG and hCGn), free fl-subunit (free f,-
hCG) and total fl-human chorionic gonadotropin (t-hCG) using different commercial kits, in a group of
bladder carcinoma patients with ectopic human chorionic gonadotropin (hCG) secretion, at diagnosis and
during treatment. The diagnostic sensitivity obtained ranged between 63.6% and 75.7% (t-hCG assays), 72.7%
(free ,B-hCG assay), 18.2% (i-hCG and hCGn) and 6% (i-hCG assay). Median increases of hCG during
treatment in patients with chemotherapy resistance ranged from 4.9 to 6.9 for t-hCG and free fl-hCG assays
and from 1.4 to 3.2 for i-hCG and i-hCG plus hCGn assays. Median decreases when chemotherapy was
efficient ranged from 2.8 to 3.3 (t-hCG and free ,B-hCG assays) and from 1.1 to 1.5 (i-hCG and i-hCG plus
hCGn assays). We conclude that t-hCG and free fl-hCG are the most suitable assays for the management of
bladder carcinoma patients as the ectopic secretion of chorionic gonadotropin is mainly due to the free fi-
subunit.
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The determination of human chorionic gonadotropin (hCG)
is especially useful in the early detection of pregnancy,
ectopic pregnancy or threatened abortion, as well as
monitoring gestational trophoblastic disease. Some germ cell
tumours are also able to synthesise hCG. Moreover, ectopic
production of hCG has been reported in non-trophoblastic
tumours in lung, liver, oesophagus, stomach, colon, kidney,
gall bladder and urinary bladder (Alfthan et al., 1992;
Hattori et al., 1980; Hoermann et al., 1992; Iles and Chard
1991).
The immunoreactive hCG substance in serum is a mixture
of hCG a- and fl-subunit-related molecules including intact
hCG, nicked hCG (with missing peptide linkages), hCG
missing the fl-subunit c-terminal segment, hCG free f,-
subunit, hCG free oc-subunit, hCG fl-subunit core fragment
and different carbohydrate variants for hCG (Cole et al.,
1992, 1993).
In most clinical situations intact hCG molecule (i-hCG) is
the predominant molecular species in peripheral blood, and
total fl-hCG assays (intact molecule plus nicked molecule plus
free P-subunit) show a reasonably good correlation with
assays which measure intact hCG alone or intact plus nicked
molecule. However, some choriocarcinomas and testicular
cancers may secrete only free fl-subunits, and assays that
measure free P-hCG or t-hCG (i-hCG plus hCGn plus free fi-
hCG) are required (Cole et al., 1994; Madersbacher et al.,
1992; Rinker et al., 1989; Saller et al., 1990). Expression of
hCG by bladder cancer is now recognised as being a common
phenomenon, the biological function of which is unknown;
clinically, it has been associated with advanced disease and
radioresistance. Assays measuring free fl-hCG have proved
useful in identifying aggressive forms of bladder cancer (Iles
et al., 1989; Iles and Chard, 1991; Marcillac et al., 1992;
Oliver et al., 1988).
We evaluated the clinical performance of assays measuring
i-hCG, i-hCG plus hCGn, free fl-hCG and t-hCG in a group
of bladder carcinoma patients at diagnosis and during
treatment. Most of the patients selected had hCG concentra-
tions above the cut-off value in order to compare the different
methods efficiently. Because t-hCG assays also show
divergent results owing to different specificity in recognising
altered forms of hCG molecules, we evaluated these
discrepancies measuring t-hCG by different commercial
assays.
Materials and methods
hCG assays
The i-hCG measure was performed with an automated
immunofluorometric enzyme assay (Stratus, Baxter Diagnos-
tics, Deerfield, IL, USA) which detects only the intact hCG
molecule with the monoclonal anti-a,f-monoclonal anti-fl
format assay.
The i-hCG plus hCGn measure was carried out with an
immunoradiometric assay (Tandem-R, Hybritech, Liege,
Belgium) with the monoclonal anti-ap-monoclonal anti-,B
format assay.
The free fl-hCG subunit was measured with an immunor-
adiometric assay (Coat-A-Count, Diagnostic Products Corp.,
Los Angeles, CA, USA) with the monoclonal anti-free fi-
polyclonal anti-free fl-format assay.
The t-hCG measure (i-hCG plus hCGn plus free fi-
subunit) was carried out with four different commercial
automated immunometric procedures: kit 1, immunochem-
iluminometric enzyme assay (Immulite, Diagnostic Products
Corp.); kit 2, immunochemiluminometric enzyme assay
(Amerlite, Kodak Diagnostics Ltd, Amersham, UK); kit 3,
immunofluorometric enzyme assay (Stratus, Baxter Diagnos-
tics Inc.) and kit 4, immunochemiluminometric assay (ACS:
180, Ciba Corning Diagnostics, Medfield, MA, USA). Kit 3
used the monoclonal anti-f-monoclonal anti-f format assay
and kits 1, 2 and 4 used the monoclonal anti-fi-polyclonal
anti-# format assay. All assays were performed as stated by
manufacturers.
Control sera and patients
We used Lyphocheck (Bio-Rad, ECS Division, Anaheim,
CA, USA) as control sera in t-hCG and i-hCG assays at
three different concentrations (L1, L2 and L3) and controls
provided by the manufacturer in free fl-hCG assay (Cl and
C2).
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Serum samples (n= 75) were obtained from 33 bladder
carcinoma patients, 30 men and three women, aged 42-75
years (mean 63, s.d. 7.5 years). The pathological tumour
stage according to the TNM classification was: five pT2, ten
pT3A, eight pT3. and ten pT4A, and histologically all were
transitional cell carcinomas (five grade II and 28 grade III).
Concentrations of hCG were measured in all these patients
and the diagnostic sensitivity (certainty of the test in
detecting sick persons correctly) using the different hCG
assays was calculated. The clinical comparison of these assays
was further performed during chemotherapy treatment in 15
patients who presented recurrence of the disease (eight
patients with chemotherapic resistance and seven patients
with clinical response to chemotherapy). During the
treatment period the median number of determinations in
each patient was three with a range between 2 and 6.
The procedures were performed in accordance with the
guidelines of the ethical committee of our hospital.
Results
Comparison assays
The results obtained in intra- and interserial precision studies
(n=20) using the control sera were within the range claimed
by the manufacturers. Intraserial imprecision obtained ranged
from 2.1% to 9.2% for i-hCG assay, from 3.5% to 10.2% for
i-hCG plus hCGn assay, from 3.8% to 6.5% for free 3-hCG
assay and from 2.3% to 9.9% for t-hCG assays. Using the
same control sera the interserial imprecision ranged from
4.9% to 11% for i-hCG assay, from 5.9% - 12.8% for i-hCG
plus hCGn assays, from 8.8% - 12.1% for free fl-hCG assay
and from 3.9% to 12.1% for t-hCG assays. To assess
correlation between the four methods measuring t-hCG in the
patient samples evaluated (n =75), we used the non-
parametric regression method of Passing-Bablok (Passing
et al., 1983). The results obtained when kit 1 was compared
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with kit 2, kit 3 and kit 4 showed a similar correlation
coefficient (r=0.96, 0.99 and 0.97) but different slopes (2.44,
1.19 and 0.74) and intercepts (1.96, 0.29 and 0.33)
respectively.
No correlation between the concentration of hCG and
tumour grade was observed.
Clinical studies
Figure 1 shows the distribution of the concentrations of t-
hCG, i-hCG plus hCGn, i-hCG and free P-hCG measured in
the serum of bladder cancer patients studied. Median
concentration, range and diagnostic sensitivity of i-hCG, i-
hCG plus hCGn, free fi-hCG and t-hCG determinations in
these patients were calculated (Table I). The diagnostic
sensitivities using t-hCG assays ranged between 63.6% and
75.7%, and was 72.7% using free fl-hCG assay; with i-hCG
plus hCGn assay the diagnostic sensitivity obtained was
18.2% and measuring the i-hCG alone the sensitivity was
6%. Table I shows the ratio (%) between free fl-hCG and t-
hCG, according to the different kits (Fan et al., 1987). These
ratios ranged between 2.2% and 6.6% (kit 2 and kit 4
respectively).
To evaluate the clinical value of the different hCG assays
studied during treatment, we calculated (Figure 2) the
increases (final/initial concentration) of free fl-hCG, t-hCG,
i-hCG plus hCGn and i-hCG concentration in the group of
patients that showed resistance to chemotherapy treatment
(n=8), and also the decrease (initial/final concentration) in
free fl-hCG, t-hCG, i-hCG plus hCGn and i-hCG concentra-
tion in the group (n = 7) with clinical response to chemother-
apy (Figure 3). Median increases obtained using free fi-hCG
assay and t-hCG assays ranged from 4.9 to 6.9 and from 1.4 to
3.2 when i-hCG and i-hCG plus hCGn assays were used.
Median decreases when chemotherapy was efficient ranged
from 2.8 to 3.3 (t-hCG and free ,B-hCG assays) and from 1.1 to
1.5 (i-hCG and i-hCG plus hCGn assays).
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Figure 1 Distribution of the concentrations of t-hCG, i-hCG
plus hCGn, i-hCG and free fl-hCG in the bladder cancer patients
studied.
Figure 2 Increases of free ,B-hCG, t-hCG, i-hCG plus hCGn and
i-hCG concentrations in a group of patients with chemotherapic
resistance (n =8).
Table I Evaluation of i-hCG, i-hCG+hCGn, t-hCG and free fl-hCG in bladder carcinoma patients (n =33)
Median Range Cut-off Diagnostic Median ratio (%)
IulrI Iur' iur sensitivity (%) fteef,/t-hCG
i-hCG 0.8 0.5-51.0 5.0 6.0
i-hCG+hCGn 0.7 0.5-467.9 5.0 18.2
t-hCG
Kit 1 6.8 1.0-12250 5.0 63.6 6.3
Kit2 25.7 2.0- 15900 5.0 75.7 2.2
Kit3 9.5 0.5- 18560 5.0 72.7 4.9
Kit4 6.6 0.7-18000 5.0 69.7 6.6
Freef,-hCG 0.5 0.04-184.2 0.1 72.7hCG assays in bladder carcinoma
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Figure 3 Decreases of free fl-hCG, t-hCG, i-hCG plus hCGn
and i-hCG concentrations in a group of patients with clinical
response to chemotherapy (n =7).
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Figure 4 Concentrations of free ,B-hCG (*-*, arithmetic scale
on the right, cut-off= 0.1IU I-'), t-hCG (+-+ kit 1, *-* kit 2,
*-0 kit 3, x-x kit 4, log scale on the left, cut-off= 5 IU -1), i-
hCG + hCGn (A-A, log scale on the left, cut-off= 5 IU I-1)
and i-hCG (M..M log scale on the left, cut-off= 5 IU I-1) during
the follow-up period of a bladder carcinoma patient.
Figure 4 is an example ofthe performance ofi-hCG, i-hCG
plus hCGn, t-hCG and free ,B concentrations during the
treatment period in a patient who is at present in complete
remission.
Discussion
The regression study among t-hCG kits showed a propor-
tional error when kit 1 was compared with kit 2, kit 3 and kit
4 (confidence intervals of the slope did not include 1.0) and a
constant error when kit 1 was compared with kit 2
(confidence intervals of the y-intercept did not include 0).
Variation in t-hCG results was not attributed to differences in
hCG standards because the four kits were standardised
against the WHO first IRP 75/537 reference material.
Moreover, the four kits used a combination of anti-#
(immobilised)-anti-fl (labelled) sandwich assay. Kit 3 was
the only kit in which both antibodies were monoclonal. Kits
1 and 4 used a polyclonal antibody as a labelled antibody
and in kit 2 the polyclonal antibody was the immobilised one.
The difference in recognition of the free # fraction by the
different antibodies used in the four t-hCG immunoassays
assayed was possibly the cause of the higher or lower results
obtained.
The diagnostic sensitivities using t-hCG assays were
similar to those obtained with free fl-hCG assay. As we
commented earlier, because the aim of our study was to
compare the efficiency of different hCG assay, we specifically
selected patients with raised hCG values and, therefore, the
diagnostic sensitivities obtained were higher than those of
other authors (Dexeus et al., 1986; Iles et al., 1989;
McLoughlin et al., 1991; Smith et al., 1994). Kit 1 and kit
4 presented the highest ratio between free fl-hCG and t-hCG,
respectively, demonstrating a higher affinity for the free fl-
hCG fraction. This is important when evaluating different t-
hCG assays because the free f-subunit and the free fl/t-hCG
ratio varied depending on the stage of tumour progression
and higher values are associated with malignant and invasive
forms of choriocarcinomas (Fan et al., 1987). As shown in
Figure 1 and in Table I, the assay measuring both fractions,
intact plus nicked hCG, performed better than the assay
measuring intact fraction alone. Recognition of nicked hCG,
however, does not seem to be crucial in the use of hCG as a
tumour marker in bladder carcinomas, as it was not in
testicular cancer (Hoerman et al., 1994).
When chemotherapy was efficient the four kits of t-hCG
studied proved to be as useful as free fl-hCG assay; however, in
more aggressive forms ofbladdercarcinoma the assays with the
best performance were the free fl-hCG and the t-hCG assays
with high free fraction affinity. There is accumulating evidence
indicating that the isolated production of free fl-hCG may be
associated with aggressive trophoblastic and non-trophoblastic
malignancies (Cole et al., 1993; Marcillac et al., 1992; Rinker et
al., 1989; Saller et al., 1990).
Like others, (Iles et al., 1989; McLoughlin et al., 1991;
Smith et al., 1994), we found no correlation between the hCG
concentration and the tumour grade. Moreover, there seems
to be no correlation between the hCG concentration and
tumour DNA-ploidy and S-phase fraction according to other
studies (Fossa et al., 1993).
In conclusion, for the routine use of serum chorionic
gonadotropin as a tumour marker in patients with bladder
carcinoma, care must be taken in choosing hCG kits as the i-
hCG and i-hCG plus hCGn concentration does not reflect the
disease and does not detect exclusive secretion of free fi
fraction. On the other hand, t-hCG assays with high affinity
for free fi fraction and the free fl-hCG assay seem to be the
most reliable and best choice in the management of
aggressive forms of bladder carcinoma.
Abbreviations
hCG, human chorionic gonadotrophin; i-hCG, intact or non-
nicked molecule of human chorionic gonadotropin; hCGn, nicked
molecule of human chorionic gonadotrophin; free ,B-hCG, free
beta subunit of human chorionic gonadotrophin; t-hCG, total beta
human chorionic gonadotropin (intact molecule plus nicked
molecule plus free ,B-subunit).
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